Tags

Type your tag names separated by a space and hit enter

Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Haemophilia. 2008 Nov; 14 Suppl 5:39-46.H

Abstract

von Willebrand disease (VWD) is a heterogeneous bleeding disorder with symptoms in affected patients ranging from mild effects to potentially devastating haemorrhagic events. Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments. Haemate P/Humate-P is an intermediate-purity VWF/FVIII concentrate with extensive clinical experience in VWD. This concentrate has been shown to correct haemostatic defects of VWD, with efficacy ratings of good/excellent in nearly all patients treated for bleeding or surgical events. Haemate P/Humate-P has a high content of the high molecular weight (HMW) VWF multimer fraction, which has been shown to be very effective in achieving haemostasis. The HMW VWF multimer pattern in Haemate P/Humate-P is more similar to that of normal human plasma (94% for Haemate P/Humate-P vs. 100% for normal human plasma) than that of other VWF/FVIII concentrates and correlates with functional VWF activities including ristocetin cofactor activity (VWF:RCo) and collagen-binding activity. The recommended dosing of Haemate P/Humate-P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. While DDAVP is effective in a large proportion of VWD patients, it may not provide adequate haemostasis in all situations. In such cases, Haemate P/Humate-P is an effective replacement concentrate for all types of VWD in both adult and paediatric patients.

Authors+Show Affiliations

Center for Thrombosis- and Haemostasis, Prof.-Hess-Kinderklinik, Klinikum Bremen-Mitte, Bremen, Germany. guenterauerswald@aol.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18786009

Citation

Auerswald, G, and W Kreuz. "Haemate P/Humate-P for the Treatment of Von Willebrand Disease: Considerations for Use and Clinical Experience." Haemophilia : the Official Journal of the World Federation of Hemophilia, vol. 14 Suppl 5, 2008, pp. 39-46.
Auerswald G, Kreuz W. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. Haemophilia. 2008;14 Suppl 5:39-46.
Auerswald, G., & Kreuz, W. (2008). Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. Haemophilia : the Official Journal of the World Federation of Hemophilia, 14 Suppl 5, 39-46. https://doi.org/10.1111/j.1365-2516.2008.01850.x
Auerswald G, Kreuz W. Haemate P/Humate-P for the Treatment of Von Willebrand Disease: Considerations for Use and Clinical Experience. Haemophilia. 2008;14 Suppl 5:39-46. PubMed PMID: 18786009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. AU - Auerswald,G, AU - Kreuz,W, PY - 2008/9/17/pubmed PY - 2008/12/17/medline PY - 2008/9/17/entrez SP - 39 EP - 46 JF - Haemophilia : the official journal of the World Federation of Hemophilia JO - Haemophilia VL - 14 Suppl 5 N2 - von Willebrand disease (VWD) is a heterogeneous bleeding disorder with symptoms in affected patients ranging from mild effects to potentially devastating haemorrhagic events. Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments. Haemate P/Humate-P is an intermediate-purity VWF/FVIII concentrate with extensive clinical experience in VWD. This concentrate has been shown to correct haemostatic defects of VWD, with efficacy ratings of good/excellent in nearly all patients treated for bleeding or surgical events. Haemate P/Humate-P has a high content of the high molecular weight (HMW) VWF multimer fraction, which has been shown to be very effective in achieving haemostasis. The HMW VWF multimer pattern in Haemate P/Humate-P is more similar to that of normal human plasma (94% for Haemate P/Humate-P vs. 100% for normal human plasma) than that of other VWF/FVIII concentrates and correlates with functional VWF activities including ristocetin cofactor activity (VWF:RCo) and collagen-binding activity. The recommended dosing of Haemate P/Humate-P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. While DDAVP is effective in a large proportion of VWD patients, it may not provide adequate haemostasis in all situations. In such cases, Haemate P/Humate-P is an effective replacement concentrate for all types of VWD in both adult and paediatric patients. SN - 1365-2516 UR - https://www.unboundmedicine.com/medline/citation/18786009/Haemate_P/Humate_P_for_the_treatment_of_von_Willebrand_disease:_considerations_for_use_and_clinical_experience_ L2 - https://doi.org/10.1111/j.1365-2516.2008.01850.x DB - PRIME DP - Unbound Medicine ER -